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Abstract  
Compared to men, women with heart failure (HF) are often older, smoke less, and 
have more preserved ejection fraction (EF), and hypertensive HF rather than HF of 
ischemic etiology. Gender-stratified outcome on comorbidities data in HF are scarce. 
Women have traditionally been under-represented in HF trials. Although data 
suggest that overall prognosis may be better in women, they experience lower 
quality of life with greater functional impairment from HF compared to men. Gender-
differences have been reported for comorbid diabetes, chronic obstructive pulmonary 
disease, renal dysfunction, anemia and depression, and may explain gender 
disparity in outcomes. However, possible confounding of comorbidities with known 
prognostic determinants in HF (such as EF) as well as gender-differences in the 
utilization of medical therapies obscures interpretation.  
In this review, we will explore the evidence for gender differences in non-
cardiovascular comorbidities in HF.  Our findings may guide clinicians to individualize 
HF care, according to best-practice, in the hope of improving prognosis for this 
chronic and debilitating condition. 
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Introduction 
The prevalence of heart failure (HF) is projected to increase substantially due 
to the ageing of populations and increased longevity1. The majority of HF patients 
suffer from comorbidities, defined as cardiovascular and non-cardiovascular chronic 
conditions that co-exist with the primary illness of HF2-5. Comorbidities put an 
additional burden on patients, healthcare utilization and expenditure for HF, and are 
associated with worse outcome4, 6, 7. Moreover, comorbidities may constitute risk 
factors for HF, trigger episodes of exacerbation, and have been proposed to drive 
the underlying disease process3, 8. A recent study providing longitudinal follow-up 
data of community-dwelling HF patients suggests that the percentage of HF patients 
with 4 or more comorbidities has increased substantially in recent years9. Another 
contemporary report showed that non-cardiovascular comorbidities constitute a 
greater hazard for hospitalizations and death than cardiovascular diseases in this 
population10. 
There is a paucity of gender-specific data on comorbidities in HF. Despite the 
fact that more than half of the patients with HF in routine care are women, 
randomized clinical trials (RCT) supporting current HF management guidelines have 
recruited predominantly male subjects with a lack of prospective gender-specific 
analyses. Some evidence, largely from registries, demonstrates important gender-
differences in HF etiology, risk factors, and clinical presentation: Women, compared 
to men, tend to be older; with higher blood pressure and non-ischemic HF etiology, 
as well as more comorbidities such diabetes, renal disease and arthritis11, 12.  
Accumulating evidence suggests better overall prognosis for women with HF 
compared to men, although it is not possible to entirely separate the impact of these 
differences according to comorbidity burden13-23.  
The Meta-Analysis Global Group In Chronic Heart Failure (MAGGIC), 
comprising individual patient data from 31 prospective observational and randomized 
studies in almost 42,000 patients with a mean follow-up of three years is currently 
the largest database containing gender-specific data in HF. MAGGIC demonstrated 
better survival for women irrespective of ejection fraction (EF) and age, although the 
gender-specific survival benefit was attenuated in subjects with ischemic etiology 
and those with comorbid diabetes9, 24. Also, the Registry to Improve the Use of 
Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) in 
HF outpatients with reduced ejection fraction showed that women were more likely to 
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have advanced CKD25. In contrast, the multicenter Organized Program to Initiate 
Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) 
registry involving 48,612 patients with HF showed a similar burden of comorbidity 
and outcomes for both genders17.  
The evidence on gender-specific outcomes appears to be different between 
acute and chronic stable HF phenotypes. The Acute Decompensated Heart Failure 
National Registry (ADHERE) database and the American Heart Association Get With 
The Guidelines-Heart Failure (GWTG-HF) registry each comprising data from 
approximately 100,000 hospitalizations reported important gender differences for 
patient characteristics for the majority of comorbidities, but similar clinical outcomes 
for both genders26, 27. Likewise, the Efficacy of Vasopressin Antagonism in Heart 
Failure Outcome Study with Tolvaptan (EVEREST) Trial in 4,133 patients 
hospitalized for HF and EF of ≤40% reported similar rates for all-cause mortality and 
CV death or HF hospitalizations for women and men23. 
Comorbidities burden in HF increase with age, may exacerbate the 
progression and clinical severity of HF, and possibly be of prognostic importance28, 
29. Several important differences between HF with reduced EF (HFrEF) compared to 
preserved EF (HFpEF; commonly defined as EF≥40%, 45% or 50%) exist where 
diabetes, anemia, chronic obstructive pulmonary disease (COPD) and obesity were 
more commonly observed in patients with HFpEF4, 26, 30, 31. In general, in women 
HFpEF is more predominant than HFrEF4, 10, 26, 27, 29, 32-34. Comorbidities exacerbate 
morbidity and mortality in HF although close relationships with other well-established 
prognostic determinants such as EF likely contribute.  
This manuscript discusses the available evidence from registries, 
administrative data from healthcare providers and clinical trials on gender-specific 
differences in major non-cardiovascular chronic conditions comorbid to HF. 
 
Diabetes 
Diabetes mellitus is not only a common and important comorbidity to HF, but also 
exerts maladaptive cardiovascular effects such as promoting coronary 
atherosclerosis, adverse myocardial remodelling, endothelial dysfunction, autonomic 
neuropathy, renal failure35. Diabetes is typically defined by clinical history, although 
some studies have distinguished between diabetes subtypes and/or insulin 
dependency. The reported prevalence of diabetes in clinical trials in HF ranges 
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between 11% and 50% (Table)4, 5, 23, 34, 36{Ghali, 2001 #13769;Simon, 2001 #13770}. 
Data from large registries such as OPTIMIZE-HF, ADHERE and GWTG-HF suggest 
a higher prevalence of diabetes of 30% to 44% in real-world patients with HF17, 26, 31, 
37. The Framingham study reported a prevalence of 26% and 14% of women and 
men with HF, respectively5, 38.  
The overall prevalence of diabetes (i.e., including both type 1 and type 2) 
among the 2,400 women and 5,199 men randomized in the Candesartan in Heart 
failure: Assessment of Reduction in Mortality and morbidity (CHARM) program was 
similar in women (30%) and in men (28%). No significant gender differences were 
found for type 2 diabetes (18% in women vs 20% in men; OR 0.95 (95% CI 0.84 to 
1.08)) but significantly more women suffered from type 1 diabetes (12% vs men 8%; 
OR 1.52 (95% CI 1.29 to 1.79); P<0.001)22.     
Gender-stratified analysis of the Cardiac Insufficiency Bisoprolol Study 
(CIBIS-II) reported a fairly low prevalence of diabetes with no significant differences 
according to gender (women 14% versus men 11%, P=0.117). Overall, women 
exhibited substantially lower rates of all-cause and cardiovascular mortality than 
men39.  
Among 5,491 patients hospitalized with new or worsening HF in relation to the 
Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) study, 
diabetes was present in 900 subjects (16%) of whom 370 were women and 530 
men33. The investigators showed that diabetes was independently associated with 
increased mortality in patients hospitalized with HF (RR: 1.5; 95% CI 1.4 to 1.6; 
p<0.0001). Of note, diabetes was associated with a larger increase in mortality in 
women than in men (RR 1.7 (95% CI 1.4 to 1.9) vs RR 1.4 (1.3 to 1.6), p<0.0001).  
In HF with preserved EF in the Irbesartan in Heart Failure with Preserved 
Ejection Fraction (I-PRESERVE) study, a trial with approximately 60% of patients 
being women, diabetes prevalence was similar in men (27%) and women (28%).  On 
multivariable analysis, no significant gender differences were found for the 
association between diabetes and clinical events40.  
In the Chronic Heart Failure Analysis and Registry in the Tohoku District-2 
(CHART-2), a prospective observational study of HF in Japan (preserved EF in 75.1 
% of women vs in 65.8% of men, P<0.001), diabetes was less prevalent in women 
(31.7%) vs men (36.4%; P=0.002). Overall survival was similar. Analysis of 
predictors for all-cause mortality between genders showed significant interaction for 
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diabetes although no detailed hazard ratios were reported41. These data are 
contrasted by a pooled analysis of prospective and observational studies from Spain. 
The multicentre Andalusian Heart Failure Registry (RAIC) examined 795 patients 
with a primary diagnosis of HF42. The relative prevalence of diabetes compared to 
men was higher in women (50.7% versus 41.2% in men, p<0.007). The authors did 
not report gender-related differences in in-hospital mortality (5.2%) or short-term 
morbidity (19.2%), and the relative importance of diabetes to these outcomes was 
not presented.  
In the MAGGIC database, diabetes was found in 25.4% of women vs 22.8% 
of men; p<0.001)24. The survival benefit in women was attenuated with comorbid 
diabetes: the hazard ratio (95% CI) of death for men vs. women without diabetes 
was 1.37 (1.30-1.45), but in the presence of diabetes only 1.11 (1.03-1.20); 
P<0.0001 for interaction)24.  
As with most other comorbidities in HF, diabetes is more frequently reported 
in registries compared to prospective randomized trials. There are important 
differences in epidemiology related to clinical HF status, with diabetes being more 
prevalent in hospitalized patients than outpatients35. The current HF literature does 
not support a consistent gender differences with regards to comorbid diabetes. 
Given the generally adverse association between diabetes and clinical outcomes, 
gender-differences in its prevalence are likely of clinical relevance. Some reports 
have demonstrated that concomitant DM attenuates the female gender benefit in 
outcomes compared to men. Thus, the negative impact of diabetes on prognosis 
might be enhanced in women, highlighting an urgent need for gender-specific 
management strategies and for prospective gender-stratified analysis in future 
studies in HF. 
 
Chronic kidney disease 
Chronic kidney disease (CKD) is another adverse prognostic indicator in HF 
subjects4, 5, 7, 36, 43-47. In previous analyses, CKD has usually been defined by past 
medical history, or determined from an estimated glomerular filtration rate (eGFR; for 
example <60 ml/min/1.73 m2). The prevalence of concomitant CKD therefore differs 
widely between 14% up to 90% in various HF cohorts (e.g., acute vs. chronic; 
preserved vs. reduced EF) and with definition used (see Table 1)17, 26, 37, 48-51. 
Registries and population-based surveys reported higher prevalence figures than 
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prospective trials which is likely due to the presence of exclusion criteria related to 
renal dysfunction in most HF trials.  
In a retrospective cohort study of 18,322 age- and gender-matched Medicare 
beneficiaries with HF (59.1% women), the relative mortality risk of comorbid CKD 
was higher than for comorbid diabetes or colorectal cancer, and only second to lung 
cancer7.  
With respect to gender, CKD has been reported more frequently in women 
with HF, while other authors reported male predominance or no gender-differences11, 
23, 34, 37. A recent epidemiological study assessing healthcare utilization and 
outcomes in Olmsted county, Minnesota, US reported a lower prevalence of CKD in 
women with both preserved EF (15% compared to men 23%) and reduced EF (14% 
versus 17%)29. 
Of note, eGFR has usually been computed using the Modification of Diet in 
Renal Disease equation (MDRD) formula which is based on serum creatinine, 
gender, age, and ethnicity, thereby potentially introducing some gender bias52. In the 
Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the 
Outpatient Setting (IMPROVE HF) the proportion of women increased with declining 
eGFR25, 53. In contrast, in the large multicenter GWTG-HF registry (n=89,127), the 
prevalence for CKD was higher in men both with reduced and preserved EF, and 
CKD was strongly associated with increased mortality for both genders37. There was 
no gender-difference in in-hospital mortality. 
In HF with preserved EF in the I-PRESERVE study, CKD was more prevalent 
in women than in men (34 vs 26%, p<0.001). Despite better overall survival in female 
patients, the presence of an eGFR <60 ml/min/1.73 m2 attenuated the survival 
advantage in women compared with men 40.  
The National HF Registry under the Spanish Society of Internal Medicine 
(RICA) included 1,772 patients (836 men [47.2%] and 936 women [52.8%]) with HF 
and mean EF of 50%. CKD was seen more often in women than men (59.1% vs 
53.0%, p<0.001) but was not associated with survival 16.  
CKD is highly prevalent and an important determinant of adverse outcome in 
HF. Registry data likely reflect the burden of comorbid CKD in HF more accurately 
than prospective trials from which HF patients with significant CKD traditionally have 
been excluded. The fact that more women with HF have hypertension, a 
predisposing condition for CKD, would provide a plausible explanation for female 
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predominance in the prevalence of CKD. Yet, comorbid CKD in HF does not seem to 
exhibit a consistent gender distribution pattern, rather, its prevalence varies 
according to HF phenotype and clinical status. Even more important, differences in 
study type, methodology, investigated cohorts and employed definitions for CKD 
likely account for most inconsistencies. Based on the negative prognostic 
association of comorbid CKD in HF and the finding by some authors of gender-
specific differences in its prevalence, gender-specific evaluation of CKD comorbid to 
HF should be the subject of prospective studies. With CKD and worsening renal 
function also frequently being the cause of discontinuation of medical therapies for 
HF, future studies should assess whether CKD requires tailored, gender-specific 
management in order to optimize outcomes in women and men with HF. 
 
Anemia and iron deficiency  
Anemia and iron deficiency are common in HF and are associated with worse 
symptoms and outcomes in HF patients54-57. Commonly anemia has been defined as 
hemoglobin levels of <12 g/dl (7.5 mmol/l) in women and <13 g/dl (<8.1 mmol/l) in 
men36. Dilutional anemia can occur in decompensated congestive HF and together 
with non-uniform cut-off definitions for anemia, may explain some discrepancies 
between HF cohorts. The reported prevalence of anemia in HF according to the 
above criteria ranges from 20-40%27, 57-61. In many HF cohorts, lower hemoglobin 
levels have been associated with higher morbidity and mortality4, 37, 58-60, 62.   
Anemia seems to be more frequent in women with HF compared with men 63-
65. In the Coordinating study evaluating Outcomes of Advising and Counseling in 
Heart failure (COACH) biomarker analysis (n=567; mean age 71 years; 38% 
women), anemia was more than twice as common in women (56% vs men 26%, 
p<0.001).   
It is important to note that anemia in heart failure is closely related to renal 
dysfunction, with complex and interacting pathophysiological mechanisms (cardio-
renal-anemia syndrome)66. This notion is supported by data from the Norwegian HF 
Registry of outpatients with advanced HF in which baseline anemia was predictive of 
all-cause mortality but not in the subset of patients with renal failure or advanced HF 
functional class67. 
The prevalence of iron deficiency in HF is at least twice that of clinically overt 
anemia55, 68. Iron plays a key role in erythropoiesis, and normal iron metabolism is 
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crucial for normal function of cardiac cells69. Iron deficiency is associated with worse 
outcomes in HF70. In a prospective observational study of 546 predominantly male 
HF patients, female gender was an independent predictor of iron deficiency69. 
Anemia is associated with older age, higher mortality both in-hospital and 
long-term, and with reduced quality of life in patients with HF. Several reports 
suggest a marked female predominance in the prevalence of anemia and iron 
deficiency in HF. Apart from gender-specific epidemiological data, little is known on 
putative gender differences in the pathophysiology, clinical course and response to 
therapy of anemia and iron deficiency in HF. Ongoing studies evaluating the role of 
iron repletion strategies in anemia or iron deficiency comorbid to HF will provide 
further insights into putative gender-specific differences of these highly prevalent 
conditions and clarify a possible need for targeted therapies according to gender. 
 
Frailty and arthritis 
Frailty is often circumscribed as the presence of general muscle weakness, fatigue, 
limited mobility, unintentional weight loss and reduced physical reserve 71-74. Frailty 
increases with age and progressive HF symptoms, and predicts death and morbidity. 
Given the vague definition and inability to distinguish physiologic frailty of aging from 
that of HF and comorbid diseases, the prevalence estimates are wide and range 
between 10% in HF outpatients and up to 74% in hospitalized HF patients74-76. 
No robust data exist on the gender distribution of frailty in HF.  
Osteoarthritis and rheumatoid arthritis are common in HF, especially in the 
elderly, and may share pathogenetic links with HF3, 5, 77-82. In particular, pro-
inflammatory mechanisms have been proposed. The reported prevalence of chronic 
knee pain and radiographic osteoarthritis according to gender in the general 
population has differed substantially, due to differences in study design definitions 
used79, 83, 84.  
As with osteoarthritis, the prevalence of rheumatoid arthritis in the general 
population, increases with age, with the presence of HF, and shows a more 
consistent female predominance85-87. Conversely, the prevalence of HF is higher in 
patients with arthritis85. In an analysis of 34,701 patients with arthritis, gender did not 
confer increased risk for HF, although the incidence of HF in that cohort was too low 
to make definitive conclusions88. Importantly, rheumatoid arthritis as a comorbidity to 
HF is associated with worse prognosis89.  
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Yet, most previous HF cohort have not systematically reported comorbid 
arthritis. A recent study in community-dwelling HF found arthritis (of any kind) to be 
more prevalent in women than men, in particular in women with HF preserved EF29. 
Together, frailty and arthritis are very common comorbidities to HF, increase 
with age and carry prognostic importance. There is a striking scarcity of gender-
specific data on the role these comorbidities in HF. Moreover, common arthritis 
therapies such as corticosteroids and non-steroidal anti-inflammatory drugs 
potentially exacerbate HF90. With polypharmacy being an increasing concern in HF 
patients, particularly in the elderly, more gender-specific evidence is also needed for 
medication use for arthritis in HF. 
 
Chronic obstructive pulmonary disease  
Chronic obstructive pulmonary disease (COPD) predicts mortality in HF91. COPD 
has been reported to be more common in male compared with female HF patients 33, 
92. Registries and RCTs show substantially higher rates of smoking in men, however 
gender differences in rates of COPD differences are less marked or absent (table)16, 
19, 27, 34, 40, 91. The GWTG-HF registry found smoking rates of 21% in males and 12% 
in females, however the prevalence of COPD was 29% in both males and females. 
The OPTIMIZE-HF registry had similar rates of smoking according to gender (21% 
males, 12 % females) with a slightly lower prevalence of COPD in females (29% vs 
26%). The EuroHeart Failure Survey II (EHFS II) demonstrated higher rates of 
smoking in males (20%) vs females (7%) and higher rates of COPD (22% vs 15% in 
females). 
The prevalence of COPD has decreased much more in men than in women in 
recent decades, a finding which has been attributed to trends in smoking patterns 
but is also thought to reflect women’s greater susceptibility to the effects of 
smoking93. Exact mechanisms for this are not understood, and hypotheses include 
that women have smaller airways leading to greater per cigarette exposure, 
differential metabolism of tobacco products and potentially also that a decrease in 
oestogen in women smokers may exacerbate pulmonary disease94. There also may 
be under-diagnosis of COPD in women due in part to a distinct clinical presentation 
compared with men. Women are less likely to present with phlegm and more likely to 
present with dyspnoea93. One study surveying physicians found that they were less 
likely to give a diagnosis of COPD to a hypothetical female than male patient with the 
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same presenting symptoms95. Diagnosing COPD in the HF population may be 
particularly complex given the overlap of symptoms and risk factors. This is 
especially true in decompensated HF as pulmonary venous congestion affects 
pulmonary function tests. In addition, the diagnosis of COPD is often particularly 
difficult in HF with preserved EF, a HF phenotype which is more common in women. 
A recent report assessing comorbidities in COPD showed a higher prevalence of HF 
in women96.  
Although COPD is a common comorbidity to HF, it is not always assessed 
and evaluated by pulmonary function tests. COPD negatively impacts on HF 
prognosis. The current literature points to male predominance in the prevalence of 
COPD comorbid to HF. A clinical challenge is the overlap in symptoms from HF and 
COPD, and further, the fact that pulmonary function tests are often unreliable in 
patients with decompensated HF. Drug interactions are another clinical problem: 
beta-blockers in HF have the potential to increase airway obstruction; in particular 
non-selective ones97. Despite proven efficacy, HF patients with COPD are therefore 
less likely to be prescribed beta-blockers. Conversely, beta-adrenergic agents and 
corticosteroids for COPD may lead to tachyarrhythmia and fluid retention98. Whether 
gender differences exist for the occurrence and severity of these important drug 
interactions should be the subject of future research.  
 
Depression  
Depression is a common comorbid condition, and often under-recognised in the HF 
population as symptoms can overlap with those of HF34, 99-105. Depression is an 
independent predictor of poor outcomes in HF patients, including death and HF 
hospitalisation99-102. It is also recognised as an independent risk factor for CAD with 
the same weight as smoking, hypertension and hyperlipidaemia106, and depression 
and HF share several biological mechanisms, including neurohormonal activation 
and increased inflammatory markers107.  
As with women in the general population, women with HF have a higher 
burden of depression than men108. A meta-analysis examining depression in HF 
found 16 studies in which gender differences were recorded, and demonstrated that 
the prevalence in women was 32.7% compared with 26.1% in men, which was 2-3 
times the rate of the general population99. Prevalence estimates varied widely in this 
study, from 11-67% in women, and 7-63% in men depending on how depression was 
12 
 
defined and which investigative tool used99. Depressive symptoms may not be 
routinely assessed in HF patients, and registries and RCTs have only infrequently 
included details on comorbid depression (see table)17, 31, 34. In the OPTIMIZE-HF 
registry of over 48,000 patients with ADHF, only 12.3% of women and 8.8% of men 
had depression. A recent study examined the gender differences in comorbid 
conditions in HF in Olmsted County, Minnesota, using a records linkage system 
which allowed virtually complete capture of health care utilisation and outcomes in 
residents29. This study found higher rates of depression in women than men, and in 
both men and women, higher rates in HFpEF than HFrEF. 
Overall, depression is a common condition in HF and exhibits a higher 
prevalence in women than men in most studies. Depression is a predictor of poor 
outcome in HF; moreover, depression severely and directly affects physical, mental 
and emotional wellbeing. In HF subjects, depression could potentially increase non-
adherence to medication and other aspects of HF management109 . In light of the 
gender disparity in prevalence, comorbid depression overall may exert greater 
detrimental effects in women with HF than men. Therefore, the lack of systematic 
gender-specific assessment of depression and the paucity of published gender-
specifc analyses is striking and calls for dedicated assessment in future work. 
 
Other non-cardiac comorbidities 
Thyroid disease is common in HF, and both abnormally low and abnormally high 
thyroid function may increase HF event rates110-113. Thyroid hormone has 
fundamental effects on CV homeostasis114, 115. The reported prevalence of abnormal 
thyroid function in women is at least twice that of men with HF. In women, abnormal 
thyroid function was reported at around 20% and 11% in OPTIMIZE-HF and EHFS II 
respectively, contrary to less than 10% in men in both studies (table 1)17, 19, 32. 
Different definitions of comorbid thyroid disease may explain differences in the 
overall prevalence between studies.  
Peripheral artery disease has been shown to predict adverse outcomes in 
acute myocardial infarction complicated with HF, reduced EF or both116. In HF, 
peripheral artery disease is another highly prevalent comorbidity, and exhibits male 
preponderance which may be due to the markedly higher percentage of male 
smokers within the same studies (table 1)16, 17, 19, 27, 34. 
13 
 
The literature on gender differences of liver disease, obesity, hyperlipidemia, 
cognitive impairment, malignancies, mental disorders and others comorbid to HF is 
limited and these comorbidities are not further discussed here. 
 
 
Summary and conclusion 
Despite some reported gender-differences in the prevalence of non-cardiovascular 
comorbidities in HF, our understanding of non-cardiovascular comorbidities in HF 
remains incomplete. Women with HF are older and more likely than men to have 
comorbid hypertension, diabetes, renal failure, obesity, depression and more severe 
symptoms, but appear to have better overall survival. Men with HF are more often 
smokers and tend to have more ischemic heart disease, COPD and HF with reduced 
EF compared with women.  
In HF clinical trials, women have traditionally been underrepresented, and 
interpretation of comorbidities is frequently obscured by non-uniform definitions, lack 
of pre-specified gender-stratification, and lack of long-term follow-up. Registries and 
administrative data from healthcare providers generally report higher prevalence 
values for comorbidities, and contrast with prospective randomized studies in the 
gender-specific distribution of comorbidities and their association with outcome.  
There is uncertainty as to whether gender-differences exist in adherence to 
guideline-directed pharmacological treatment of HF as well as that of comorbidities, 
and whether such differences are of prognostic relevance.  
Temporal changes in epidemiology suggest an increasing incidence of HFpEF 
compared to HFrEF, higher comorbidity burden and female predominance with the 
aging of HF cohorts4, 10, 29, 117. 
Combined efforts from regulators, trialists, health authorities and registry 
administrators are required to adequately fill our knowledge gap on gender-specific 
differences in epidemiology, pathogenesis, therapeutic management and prognostic 
significance of comorbidities in HF. There is an unmet need and a great opportunity 
for clinicians to assess whether gender-related differences in comorbidities of HF 
require specific management strategies. 
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